APA (7th ed.) Citation

L, D. F., M, M., C, S., & M, R. (2026). Managing myelofibrosis in the frailty era: The expanding role of JAK inhibitors. Leukemia & lymphoma, 67(6), 1257. https://doi.org/10.1080/10428194.2026.2655442

Chicago Style (17th ed.) Citation

L, De Fazio, Molica M, Simio C, and Rossi M. "Managing Myelofibrosis in the Frailty Era: The Expanding Role of JAK Inhibitors." Leukemia & Lymphoma 67, no. 6 (2026): 1257. https://doi.org/10.1080/10428194.2026.2655442.

MLA (9th ed.) Citation

L, De Fazio, et al. "Managing Myelofibrosis in the Frailty Era: The Expanding Role of JAK Inhibitors." Leukemia & Lymphoma, vol. 67, no. 6, 2026, p. 1257, https://doi.org/10.1080/10428194.2026.2655442.